Podocyturia: why it may have added value in rare diseases

Abstract Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone mi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical kidney journal 2019-02, Vol.12 (1), p.49-52
Main Authors: Sanchez-Niño, Maria Dolores, Perez-Gomez, Maria Vanessa, Valiño-Rivas, Lara, Torra, Roser, Ortiz, Alberto
Format: Article
Language:English
Subjects:
Biopharmaceuticals
Care and treatment
Cells (Biology)
Diseases
Enzyme therapy
Enzymes
Fabry's disease
Familial Nephropathies
Genes
Health aspects
Kidney diseases
Lipids
Migalastat
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to α-galactosidase-A deficiency, and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi.org/10.1093/ckj/sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost from detached urinary podocytes.
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfy081